Literature DB >> 34074763

Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase.

Simon Klaessens1,2, Vincent Stroobant1,2, Delia Hoffmann1,2, Mads Gyrd-Hansen3, Luc Pilotte1,2, Nathalie Vigneron1,2, Etienne De Plaen1,2, Benoit J Van den Eynde4,2,3,5.   

Abstract

Maintaining stable tryptophan levels is required to control neuronal and immune activity. We report that tryptophan homeostasis is largely controlled by the stability of tryptophan 2,3-dioxygenase (TDO), the hepatic enzyme responsible for tryptophan catabolism. High tryptophan levels stabilize the active tetrameric conformation of TDO through binding noncatalytic exosites, resulting in rapid catabolism of tryptophan. In low tryptophan, the lack of tryptophan binding in the exosites destabilizes the tetramer into inactive monomers and dimers and unmasks a four-amino acid degron that triggers TDO polyubiquitination by SKP1-CUL1-F-box complexes, resulting in proteasome-mediated degradation of TDO and rapid interruption of tryptophan catabolism. The nonmetabolizable analog alpha-methyl-tryptophan stabilizes tetrameric TDO and thereby stably reduces tryptophanemia. Our results uncover a mechanism allowing a rapid adaptation of tryptophan catabolism to ensure quick degradation of excess tryptophan while preventing further catabolism below physiological levels. This ensures a tight control of tryptophanemia as required for both neurological and immune homeostasis.

Entities:  

Keywords:  tryptophan; tryptophan 2,3-dioxygenase; ubiquitination

Mesh:

Substances:

Year:  2021        PMID: 34074763      PMCID: PMC8201853          DOI: 10.1073/pnas.2022447118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities.

Authors:  Roland Hjerpe; Fabienne Aillet; Fernando Lopitz-Otsoa; Valerie Lang; Patrick England; Manuel S Rodriguez
Journal:  EMBO Rep       Date:  2009-10-02       Impact factor: 8.807

2.  Hypertryptophanemia due to tryptophan 2,3-dioxygenase deficiency.

Authors:  Patrick Ferreira; Inchul Shin; Iveta Sosova; Kednerlin Dornevil; Shailly Jain; Deborah Dewey; Fange Liu; Aimin Liu
Journal:  Mol Genet Metab       Date:  2017-03-01       Impact factor: 4.797

3.  Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.

Authors:  Delia Hoffmann; Tereza Dvorakova; Vincent Stroobant; Caroline Bouzin; Aurélie Daumerie; Marie Solvay; Simon Klaessens; Marie-Claire Letellier; Jean-Christophe Renauld; Nicolas van Baren; Julie Lelotte; Etienne Marbaix; Benoit J Van den Eynde
Journal:  Cancer Immunol Res       Date:  2019-12-05       Impact factor: 11.151

4.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

Review 5.  Kynurenines in the mammalian brain: when physiology meets pathology.

Authors:  Robert Schwarcz; John P Bruno; Paul J Muchowski; Hui-Qiu Wu
Journal:  Nat Rev Neurosci       Date:  2012-07       Impact factor: 34.870

6.  Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Authors:  Holly K Koblish; Michael J Hansbury; Kevin J Bowman; Gengjie Yang; Claire L Neilan; Patrick J Haley; Timothy C Burn; Paul Waeltz; Richard B Sparks; Eddy W Yue; Andrew P Combs; Peggy A Scherle; Kris Vaddi; Jordan S Fridman
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

7.  A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment.

Authors:  Marc L Hyer; Michael A Milhollen; Jeff Ciavarri; Paul Fleming; Tary Traore; Darshan Sappal; Jessica Huck; Judy Shi; James Gavin; Jim Brownell; Yu Yang; Bradley Stringer; Robert Griffin; Frank Bruzzese; Teresa Soucy; Jennifer Duffy; Claudia Rabino; Jessica Riceberg; Kara Hoar; Anya Lublinsky; Saurabh Menon; Michael Sintchak; Nancy Bump; Sai M Pulukuri; Steve Langston; Stephen Tirrell; Mike Kuranda; Petter Veiby; John Newcomb; Ping Li; Jing Tao Wu; Josh Powe; Lawrence R Dick; Paul Greenspan; Katherine Galvin; Mark Manfredi; Chris Claiborne; Benjamin S Amidon; Neil F Bence
Journal:  Nat Med       Date:  2018-01-15       Impact factor: 53.440

Review 8.  Mechanisms and function of substrate recruitment by F-box proteins.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Mol Cell Biol       Date:  2013-05-09       Impact factor: 94.444

Review 9.  Amino acid homeostasis and signalling in mammalian cells and organisms.

Authors:  Stefan Bröer; Angelika Bröer
Journal:  Biochem J       Date:  2017-05-25       Impact factor: 3.857

10.  CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling.

Authors:  Matous Hrdinka; Berthe Katrine Fiil; Mattia Zucca; Derek Leske; Katrin Bagola; Monica Yabal; Paul R Elliott; Rune Busk Damgaard; David Komander; Philipp J Jost; Mads Gyrd-Hansen
Journal:  Cell Rep       Date:  2016-03-17       Impact factor: 9.423

View more
  2 in total

1.  Human cytosolic transaminases: side activities and patterns of discrimination towards physiologically available alternative substrates.

Authors:  Francesco Caligiore; Erika Zangelmi; Carola Vetro; Takfarinas Kentache; Joseph P Dewulf; Maria Veiga-da-Cunha; Emile Van Schaftingen; Guido Bommer; Alessio Peracchi
Journal:  Cell Mol Life Sci       Date:  2022-07-14       Impact factor: 9.207

Review 2.  Systemic tryptophan homeostasis.

Authors:  Simon Klaessens; Vincent Stroobant; Etienne De Plaen; Benoit J Van den Eynde
Journal:  Front Mol Biosci       Date:  2022-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.